Invesco Exchange-Traded Fund Trust II has provided an update on its financial status through its recent filing. The report, submitted on October 30, 2026, indicates the fund's total assets stand at approximately $38.3 million, with net assets close to $30.3 million. This information is crucial as it reflects the fund's operational health and its competitive stance in the investment landscape.
The Invesco Exchange-Traded Fund Trust II, which operates under the SEC file number 811-21977, is categorized as an investment entity. The fund is known for its Invesco S&P SmallCap Financials ETF, which aims to provide investors with exposure to small-cap financial companies. The latest filing is part of a series of submissions, with several other NPORT-P forms filed on the same date, indicating active management and reporting by the trust.
According to the filing, the total liabilities of the fund amount to approximately $7.99 million. The report also highlights the fund's performance metrics, including monthly total returns which reflect the fund's ability to navigate market conditions. For instance, the fund reported a monthly total return of 6.68% for one month, followed by 3.18% and a negative return of -1.70% in subsequent months.
The filing also details the fund's investment strategies and holdings, showcasing a diversified portfolio. Notably, the fund has made investments in various corporations, including Independent Bank Corp., Jackson Financial Inc., and Seacoast Banking Corp. of Florida, among others. These investments are crucial as they contribute to the fund's overall performance and risk profile.
This update may affect various stakeholders, including investors looking for opportunities in the small-cap financial sector. The detailed financials provide insight into the fund's management and investment strategies, which could influence investor confidence and decisions moving forward.
As for the next steps, the filing does not specify any forthcoming actions or decisions. However, the ongoing monitoring of the fund's performance and additional filings will be essential for stakeholders interested in the fund's trajectory.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






